We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Refinitiv and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from our Featured Companies page.
ANGLE
Adapting to align with the biggest future opportunitiesFutura Medical
Home use study supports WSD4000 developmentOxford BioDynamics
Fundraise of £7m provides much needed cashHUTCHMED
Advancing innovation and increasing core business focusScancell
Poised for several pivotal clinical events in 2025Arecor Therapeutics
Tetris Pharma to be wound down; Ogluo rights returnedArecor Therapeutics
New licence adds AT351 to partnered pipelineHUTCHMED
ASH 2024: long-term data show sovleplenib benefitScancell
Fundraise extends cash into H226 beyond key catalystsScancell
Genmab strikes second GlyMab deal